BISOPROLOL

💡

Quick Summary

Bisoprolol is a highly cardioselective beta-1 adrenergic receptor blocker used primarily for the management of hypertension and stable chronic heart failure. It works by competitively inhibiting beta-1 receptors in the myocardium, reducing heart rate, myocardial contractility, and cardiac output, which lowers blood pressure and decreases myocardial oxygen demand. It is indicated for adults with hypertension and, in combination with standard therapies, for stable chronic heart failure with reduced ejection fraction. The most critical clinical consideration is avoiding abrupt discontinuation, which can precipitate rebound tachycardia, angina exacerbation, or myocardial infarction, necessitating a gradual dose taper over at least one to two weeks.

🔬

Drug Identity

GENERIC NAMEBisoprolol
MEDOBO IDMDBD0069
ATC CODEC07AB07
PHARMACOLOGICAL CLASSCardioselective Beta-1 Adrenergic Receptor Blocker
THERAPEUTIC CLASSAntihypertensive and Heart Failure Agent
THERAPEUTIC CATEGORYCardiovascular
CHEMICAL NAME(±)-1-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]-2-propanol hemifumarate
DRUG SOURCESynthetic
FDA APPROVAL1992
MODALITYSmall Molecule
DRUG TYPEstandard
MARKET STATUS● Approved
CORE USE TAGS
AntihypertensiveHeart FailureBeta-BlockerCardioselectiveAngina
BRAND NAMES (GLOBAL)
ZebetaConcorCardensielEmcorCongescorCorbisBicorZiac
SYNONYMS
Bisoprolol fumarateBisoprolol hemifumarate
📌

Indications & Uses

🎯 APPROVED INDICATIONS
  • Hypertension — as monotherapy or in combination with other antihypertensive agents (e.g., thiazide diuretics).
  • Stable chronic heart failure — in combination with angiotensin-converting enzyme (ACE) inhibitors, diuretics, and optionally digoxin, to reduce mortality and cardiovascular hospitalizations in patients with New York Heart Association (NYHA) class II-IV heart failure and reduced ejection fraction.
🔬 OFF-LABEL USES
  • Atrial fibrillation — ventricular rate control.
  • Angina pectoris — prophylaxis and management of chronic stable angina.
  • Post-myocardial infarction — secondary prevention in patients intolerant to other beta-blockers.
MEDICAL DISCLAIMER — This content is intended for educational purposes and qualified healthcare professionals only. Always refer to current prescribing information, institutional protocols, and official clinical guidelines. Medobo is not responsible for clinical decisions made based on this content.